Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATTO-1091
- Development stage
- Preclinical
- Lead developer
- Attovia Therapeutics
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
ATTO-1091 is a trispecific antibody therapeutic candidate being developed by Attovia Therapeutics for the treatment of inflammatory bowel disease (IBD). It is engineered using the company's proprietary ATTOBODY™ platform, which enables the creation of multispecific biologics capable of binding to multiple epitopes or targets simultaneously with high affinity. ATTO-1091 is designed to inhibit three distinct disease-driving pathways within a single molecule to provide a more comprehensive approach to the complex immune-mediated pathology of IBD. As of early 2025, the program is in the IND-enabling phase of development.
Beyond the preview
Go deeper on ATTO-1091.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATTO-1091.